Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tamtero
- Development stage
- Unknown
- Lead developer
- Azista Bhutan Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tamtero is an oncology medication containing tamoxifen citrate, a nonsteroidal selective estrogen receptor modulator (SERM). Developed and marketed by Azista Bhutan Healthcare, it is indicated for the treatment of early-stage breast cancer in women who have already undergone surgery, chemotherapy, or radiation, as well as for reducing the incidence of breast cancer in high-risk patients. Tamtero works by competitively binding to estrogen receptors in breast tissue, thereby blocking the effects of estrogen that support the development and proliferation of estrogen receptor-positive breast cancers.
- Brand names
- Tamtero
- Other names
- tamoxifen citrate
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on Tamtero.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tamtero.